Integrating Network Pharmacology, Transcriptomics to Reveal Neuroprotective of Curcumin Activate PI3K / AKT Pathway in Parkinson’s Disease

References

• Dorsey ER, Sherer T, Okun MS, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3–S8. doi:10.3233/JPD-181474
   PubMedGoogle Scholar
• Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and Pathogenesis of Parkinson’s Syndrome. Annu Rev Pathol. 2023;18:95–121. doi:10.1146/annurev-pathmechdis-031521-034145
   PubMed Web of Science ®Google Scholar
• Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272. doi:10.1016/S1474-4422(16)30230-7
   PubMed Web of Science ®Google Scholar
• Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19(2):179–194. doi:10.1016/S1474-4422(19)30356-4
   PubMed Web of Science ®Google Scholar
• Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303. doi:10.1016/S0140-6736(21)00218-X
   PubMed Web of Science ®Google Scholar
• Vijiaratnam N, Simuni T, Bandmann O, Morris HR, Foltynie T. Progress towards therapies for disease modification in Parkinson’s disease. Lancet Neurol. 2021;20(7):559–572. doi:10.1016/S1474-4422(21)00061-2
   PubMed Web of Science ®Google Scholar
• Kocaadam B, Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr. 2017;57(13):2889–2895. doi:10.1080/10408398.2015.1077195
   PubMed Web of Science ®Google Scholar
• Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. Food Funct. 2018;9(2):705–714. doi:10.1039/c7fo01242j
   PubMed Web of Science ®Google Scholar
• Bhat A, Mahalakshmi AM, Ray B, et al. Benefits of curcumin in brain disorders. Biofactors. 2019;45(5):666–689. doi:10.1002/biof.1533
   PubMed Web of Science ®Google Scholar
• Yeung AWK, Tzvetkov NT, Georgieva MG, et al. Reactive oxygen species and their impact in neurodegenerative diseases: literature landscape analysis. Antioxid Redox Signal. 2021;34(5):402–420. doi:10.1089/ars.2019.7952
   PubMed Web of Science ®Google Scholar
• Mollazadeh H, Cicero AFG, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: the role of interleukin-10. Crit Rev Food Sci Nutr. 2019;59(1):89–101. doi:10.1080/10408398.2017.1358139
   PubMed Web of Science ®Google Scholar
• Pandey N, Strider J, Nolan WC, Yan SX, Galvin JE. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008;115(4):479–489. doi:10.1007/s00401-007-0332-4
   PubMed Web of Science ®Google Scholar
• Zhong L, Cai B, Wang Q, Li X, Xu W, Chen T. Exploring the neuroprotective mechanism of curcumin inhibition of intestinal inflammation against Parkinson’s disease based on the gut-brain axis. Pharmaceuticals. 2022;16(1). doi:10.3390/ph16010039
   Web of Science ®Google Scholar
• Cai B, Zhong L, Wang Q, Xu W, Li X, Chen T. Curcumin alleviates 1-methyl- 4-phenyl- 1,2,3,6-tetrahydropyridine- induced Parkinson’s disease in mice via modulating gut microbiota and short-chain fatty acids. Front Pharmacol. 2023;14:1198335. doi:10.3389/fphar.2023.1198335
   PubMed Web of Science ®Google Scholar
• Long HZ, Cheng Y, Zhou ZW, Luo HY, Wen DD, Gao LC. PI3K/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer’s disease and Parkinson’s disease. Front Pharmacol. 2021;12:648636. doi:10.3389/fphar.2021.648636
   PubMed Web of Science ®Google Scholar
• Elstner M, Morris CM, Heim K, et al. Expression analysis of dopaminergic neurons in Parkinson’s disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol. 2011;122(1):75–86. doi:10.1007/s00401-011-0828-9
   PubMed Web of Science ®Google Scholar
• Jin T, Zhang Y, Botchway BOA, et al. Curcumin can improve Parkinson’s disease via activating BDNF/PI3k/Akt signaling pathways. Food Chem Toxicol. 2022;164:113091. doi:10.1016/j.fct.2022.113091
   PubMed Web of Science ®Google Scholar
• Wu J, Li M, Huang N, et al. Curcumin alleviates high-fat diet-induced nonalcoholic steatohepatitis via improving hepatic endothelial function with microbial biotransformation in rats. J Agric Food Chem. 2023;71(27):10338–10348. doi:10.1021/acs.jafc.3c01067
   PubMed Web of Science ®Google Scholar
• Shi HH, Chen LP, Wang CC, et al. Docosahexaenoic acid-acylated curcumin diester alleviates cisplatin-induced acute kidney injury by regulating the effect of gut microbiota on the lipopolysaccharide- and trimethylamine-N-oxide-mediated PI3K/Akt/NF-kappaB signaling pathway in mice. Food Funct. 2022;13(11):6103–6117. doi:10.1039/d1fo04178a
   PubMed Web of Science ®Google Scholar
• Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682–690. doi:10.1038/nchembio.118
   PubMed Web of Science ®Google Scholar
• Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt H. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci. 2022;43(2):136–150. doi:10.1016/j.tips.2021.11.004
   PubMed Web of Science ®Google Scholar
• Dong Z, Chen Y. Transcriptomics: advances and approaches. Sci China Life Sci. 2013;56(10):960–967. doi:10.1007/s11427-013-4557-2
   PubMed Web of Science ®Google Scholar
• Prasad EM, Hung SY. Behavioral tests in neurotoxin-induced animal models of Parkinson’s disease. Antioxidants. 2020;9(10). doi:10.3390/antiox9101007
   Web of Science ®Google Scholar
• Kumar A, Chetia H, Sharma S, Kabiraj D, Talukdar NC, Bora U. Curcumin resource database. Database. 2015;2015:bav070. doi:10.1093/database/bav070
   PubMedGoogle Scholar
• The Gene Ontology, C. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 2019;47(D1):D330–D338. doi:10.1093/nar/gky1055
   PubMed Web of Science ®Google Scholar
• Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res. 2008;36(Database issue):D480–484. doi:10.1093/nar/gkm882
   PubMed Web of Science ®Google Scholar
• LeWitt PA. Levodopa therapy for Parkinson’s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64–72. doi:10.1002/mds.26082
   PubMed Web of Science ®Google Scholar
• Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord. 2016;31(11):1602–1609. doi:10.1002/mds.26712
   PubMed Web of Science ®Google Scholar
• Peng H, Li Y, Ji W, et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease. ACS Nano. 2022;16(1):869–884. doi:10.1021/acsnano.1c08473
   PubMed Web of Science ®Google Scholar
• Liu J, Liu C, Zhang J, et al. A self-assembled alpha-synuclein nanoscavenger for Parkinson’s disease. ACS Nano. 2020;14(2):1533–1549. doi:10.1021/acsnano.9b06453
   PubMed Web of Science ®Google Scholar
• Perez-Pi I, Evans DA, Horrocks MH, et al. alpha-Synuclein-Confocal Nanoscanning (ASYN-CONA), a bead-based assay for detecting early-stage alpha-synuclein aggregation. Anal Chem. 2019;91(9):5582–5590. doi:10.1021/acs.analchem.8b03842
   PubMed Web of Science ®Google Scholar
• Zhang N, Yan F, Liang X, et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson’s disease therapy. Theranostics. 2018;8(8):2264–2277. doi:10.7150/thno.23734
   PubMed Web of Science ®Google Scholar
• Moujalled D, Strasser A, Liddell JR. Molecular mechanisms of cell death in neurological diseases. Cell Death Differ. 2021;28(7):2029–2044. doi:10.1038/s41418-021-00814-y
   PubMed Web of Science ®Google Scholar
• Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112:24–49. doi:10.1016/j.pneurobio.2013.10.004
   PubMed Web of Science ®Google Scholar
• Yuan J, Amin P, Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019;20(1):19–33. doi:10.1038/s41583-018-0093-1
   PubMed Web of Science ®Google Scholar
• Gu C, Wang F, Zhang YT, et al. Microglial MT1 activation inhibits LPS-induced neuroinflammation via regulation of metabolic reprogramming. Aging Cell. 2021;20(6):e13375. doi:10.1111/acel.13375
   PubMed Web of Science ®Google Scholar
• Zhao YF, Qiong Z, Zhang JF, et al. The synergy of aging and LPS exposure in a mouse model of Parkinson’s disease. Aging Dis. 2018;9(5):785–797. doi:10.14336/AD.2017.1028
   PubMed Web of Science ®Google Scholar
• Kumar A, Chen SH, Kadiiska MB, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med. 2014;73:51–59. doi:10.1016/j.freeradbiomed.2014.04.014
   PubMed Web of Science ®Google Scholar
• Singh S, Das T, Ravindran A, et al. Involvement of nitric oxide in neurodegeneration: a study on the experimental models of Parkinson’s disease. Redox Rep. 2005;10(2):103–109. doi:10.1179/135100005X38842
   PubMed Web of Science ®Google Scholar
• Wang G, Pan J, Chen SD. Kinases and kinase signaling pathways: potential therapeutic targets in Parkinson’s disease. Prog Neurobiol. 2012;98(2):207–221. doi:10.1016/j.pneurobio.2012.06.003
   PubMed Web of Science ®Google Scholar
• Xu F, Na L, Li Y, Chen L. Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci. 2020;10(1):54. doi:10.1186/s13578-020-00416-0
   PubMed Web of Science ®Google Scholar
• Miao L, Yang L, Huang H, Liang F, Ling C, Hu Y. mTORC1 is necessary but mTORC2 and GSK3beta are inhibitory for AKT3-induced axon regeneration in the central nervous system. Elife. 2016;5:e14908. doi:10.7554/eLife.14908
   PubMed Web of Science ®Google Scholar
• Xiang H, Zhang J, Lin C, Zhang L, Liu B, Ouyang L. Targeting autophagy-related protein kinases for potential therapeutic purpose. Acta Pharm Sin B. 2020;10(4):569–581. doi:10.1016/j.apsb.2019.10.003
   PubMed Web of Science ®Google Scholar
• Gupta R, Sahu M, Srivastava D, Tiwari S, Ambasta RK, Kumar P. Post-translational modifications: regulators of neurodegenerative proteinopathies. Ageing Res Rev. 2021;68:101336. doi:10.1016/j.arr.2021.101336
   PubMed Web of Science ®Google Scholar
• Patel SS, Acharya A, Ray RS, Agrawal R, Raghuwanshi R, Jain P. Cellular and molecular mechanisms of curcumin in prevention and treatment of disease. Crit Rev Food Sci Nutr. 2020;60(6):887–939. doi:10.1080/10408398.2018.1552244
   PubMed Web of Science ®Google Scholar
• Hatami M, Abdolahi M, Soveyd N, Djalali M, Togha M, Honarvar NM. Molecular mechanisms of curcumin in neuroinflammatory disorders: a mini review of current evidences. Endocr Metab Immune Disord Drug Targets. 2019;19(3):247–258. doi:10.2174/1871530319666181129103056
   PubMed Web of Science ®Google Scholar
• van der Merwe C, van Dyk HC, Engelbrecht L, et al. Curcumin rescues a PINK1 knock down SH-SY5Y cellular model of Parkinson’s disease from mitochondrial dysfunction and cell death. Mol Neurobiol. 2017;54(4):2752–2762. doi:10.1007/s12035-016-9843-0
   PubMed Web of Science ®Google Scholar
• Wang XS, Zhang ZR, Zhang MM, Sun MX, Wang WW, Xie CL. Neuroprotective properties of curcumin in toxin-base animal models of Parkinson’s disease: a systematic experiment literatures review. BMC Complement Altern Med. 2017;17(1):412. doi:10.1186/s12906-017-1922-x
   PubMed Web of Science ®Google Scholar